Biggest News Aggregation in the World
📰 Looking Statement News

Page 43 - Looking Statement News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Looking Statement. Real-time updates on events, politics, business and more.

Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789

28.02.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-641 and KEYNOTE-789. Merck is discontinuing the Phase 3 KEYNOTE-641 trial evaluating KEYTRUDA (pembrolizumab), Merck’s ...
United States Eliav Barr Merck Research Laboratories Statement Of Merck Co Inc Exchange Commission Merck Co Inc

Moderna, Inc.: Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA , was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanom

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trialCAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering
United States United Kingdom Lavina Talukdar Erich Rubin Julie Cunningham Dennis Riedl

Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-expos

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19. The Phase 3...
United States United Kingdom Eastern Cape South Africa Julie Cunningham Deb Wambold

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19

21.02.2023 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual ...
United States United Kingdom Eastern Cape South Africa Ridgeback Biotherapeutics Us Department Of Defense

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progr

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of clinical data from its broad and advancing cardiovascular pipeline and portfolio at the upcoming American College of Cardiology’s 72nd Annual Scientific Session toget...
United States Julie Cunningham Peter Dannenbaum Damini Chokshi Eliav Barr World Heart Federation Congress

Technip Energies Selected by Arcadia eFuels for the World's First Commercial Facility to Produce eFuels from Renewable Electricity and Captured CO2

Technip Energies (PARIS: TE) has been awarded a Front-End Engineering and Design (FEED) contract by Arcadia eFuels for the world's first commercial eFuels facility for sustainable aviation fuels production
United States Dennis Riedl Phil Lindsay Amy Hebert Technip Energie Laure Mandrou

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science